Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 105 of 126 results for thyroid* OR hypothyroid* OR Hyperthyroid* OR goiter

  1. Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)

    Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humatrope, Norditropin, NutropinAq, Omnitrope, Saizen, Zomacton) for treating growth failure in children.

    Technology appraisal guidance
    Published
    26 May 2010
    View recommendations

    Sections for TA188

  2. Radioactive iodine: What is the clinical and cost effectiveness of RAI after total or completion thyroidectomy for people with T2 disease and no adverse pathological features?

    the clinical and cost effectiveness of RAI after total or completion thyroidectomy for people with T2 disease and no adverse...

    Research recommendation
    Published
    6 January 2023

  3. External beam radiotherapy compared with usual care: What is the clinical and cost effectiveness of external beam radiotherapy for people with residual or recurrent thyroid cancer?

    effectiveness of external beam radiotherapy for people with residual or recurrent thyroid cancer? Any explanatory notes(if applicable)...

    Research recommendation
    Published
    6 January 2023

  4. Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333)

    Evidence-based recommendations on axitinib (Inlyta) for previously treated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    25 February 2015
    View recommendations

    Sections for TA333

  5. Sunitinib for the treatment of gastrointestinal stromal tumours (TA179)

    Evidence-based recommendations on sunitinib (Sutent) for treating gastrointestinal stromal tumours in adults.

    Technology appraisal guidance
    Published
    23 September 2009
    View recommendations

    Sections for TA179

  6. Thyroid disease

    Awaiting development [GID-QS10088] Expected publication date: TBC

    Quality standard
    Awaiting development

  7. Sparsentan for treating primary IgA nephropathy ID6308

    In development [GID-TA11359] Expected publication date: 11 December 2024

    Technology appraisal guidance
    In development

  8. Percutaneous Laser Ablation (PLA) for benign thyroid nodules

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  9. Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 23 May 2024.

    Technology appraisal guidance
    In consultation

  10. Teprotumumab for treating thyroid eye disease ID 6432

    Awaiting development [GID-TA11531] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16)

    Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the

    Diagnostics guidance
    Published
    10 December 2014
    View recommendations

    Sections for DG16

  12. Cost saving guidance

    NICE guidance that could generate cost savings.

  13. Supporting the health and care system in improving productivity

    Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.

  14. Managed access

    Managed access allows patients to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.

  15. Past appeals and decisions

    TA928 Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine 19...